Vol. IV · No. 19
Monday, May 18, 2026
Issue: Spring · 2026
Established · MMXXVI
— The evidence base for longevity medicine —
Indexed by PubMed · CTG · Cochrane
Editorial team · geroevidence.com
Subscription · app.geroevidence.com
Geroevidence · Roadmap

What is coming

Geroevidence is a young platform. We currently track 8 interventions. This page shows what we are building next — new compounds, pipeline improvements, and platform features. Updated as priorities shift.

Last updated: May 2026 · Questions · hello@geroevidence.com
§ Now
Live today
May 2026
8 interventions tracked
Rapamycin, Metformin, GLP-1 agonists, SGLT2 inhibitors, NMN, NR, D+Q senolytics, Acarbose — each with mechanism summary, evidence tier, and key outcome.
Daily literature pipeline
PubMed indexed daily at 6am UTC. Every paper reviewed by the editorial team before reaching subscribers. No automated content.
Evidence alert feed
Practice-changing, new evidence, and informational alerts organized by severity. Filterable by intervention.
Active trial tracking
ClinicalTrials.gov data for each intervention. Phase, enrollment, primary endpoint, estimated completion.
§ Q3 2026
6 months
Jul – Sep 2026
New interventions
Taurine
Amino acid · AMPK modulator
Singh 2023 mouse lifespan + human trial data emerging
Berberine
AMPK activator · glucose
Metformin comparator data; growing longevity interest
17α-Estradiol
Non-feminizing estrogen
ITP lifespan extension in male mice; NCT recruiting
Spermidine
Polyamine · autophagy
Phase II data on cognitive endpoints; Madeo lab
Urolithin A
Mitophagy activator
Amazentis Phase II muscle data; NAD+ adjacent
Fisetin
Senolytic flavonoid
Mayo Clinic trials ongoing; D+Q complement
Platform
bioRxiv / medRxiv preprints
Pre-publication signal for fast-moving areas. Clearly labelled as not peer reviewed.
Weekly email digest
Monday morning brief — evidence changes, new trials recruiting, papers of the week. One email, no noise.
Intervention tracking
Pin the interventions you follow most closely. Dashboard and alert feed personalized to your tracked list.
Team reading queue
Shared reading queue for team plan subscribers. Flag papers for colleagues.
§ Q1 2027
12 months
Jan – Mar 2027
Further interventions
Target: 20+ tracked interventions. Next candidates after Q3 cohort include α-Ketoglutarate, NAD+ IV, Lithium (low-dose), Dasatinib monotherapy, Glycine + NAC, and Klotho agonists as trial data matures. Interventions are added when a minimum evidence threshold is met — at least one published human trial or strong ITP lifespan data.
Platform
Evidence change history
Full audit trail of evidence tier changes per intervention. When did Moderate become Strong and why.
Trial readout calendar
Upcoming trial completion dates surfaced to subscribers. TAME, PEARL-3, SIRO-COG and others.
Conference abstract monitoring
ADA, ACC, AGE conference abstracts ingested at event time. Fast signal before journal publication.
Cochrane integration
Systematic review and meta-analysis indexing from Cochrane Library for relevant interventions.
§ Not building
Out of scope

Geroevidence is a clinical evidence reference, not a clinical decision support tool. We are deliberately not building: patient-facing content, drug interaction checkers, dosing calculators, biomarker tracking, cohort management, or anything that moves toward practicing medicine.

We are also not adding advertising, sponsored content, or pharma partnerships. The credibility of the evidence summaries depends on editorial independence. This will not change.

Missing an intervention?
Subscribers can suggest interventions directly from the app. We prioritize based on evidence base and subscriber demand.
Start free trial Contact us